medigraphic.com
ISSN 0188-9796 (Print)

2011, Number 1

<< Back Next >>

Rev Endocrinol Nutr 2011; 19 (1)

Comparison of two 131I doses (20 vs 29 mCi) in the treatment of autoimmune hyperthyroidism

Gómez-Cruz JR

Language: Spanish
References: 21
Page: 17-20
PDF size: 64.60 Kb.


ABSTRACT

Background: The treatment o autoimmune hyperthyroidism includes beta blockers, methimazole (MTZ) and radioiodine (131I). 131I doses vary from 10 to 29 mCi and the development of hypothyroidism is positively correlated with the administered amount. Objective: To compare the rate of hypothyroidism after 20 and 29 mCi doses of 131I in patients with autoimmune hyperthyroidism. Methods: Patients 18 years and older, with primary hyperthyroidism were selected according to the following criteria: a) diffuse palpable goiter, b) exophtalmos and/or c) thyroid scan with diffuse goiter. Patients were first treated with MTZ and after achieving the euthyroid state, theye were randomized to receive either 29 or 20 mCi of 131I. Results: We included 22 patients, age 38 ± 11,8 years, 19 women (79%). 9 patients received 20 mCi of 131I and 13, 29 mCi. Patients were treated with MTZ prior to the 131I, 3 months for 2-6 months. 8/9 patients (88%) of the 20 mCi group developed hypothyroidism after 2-8 months, the remaining patient is euthyroid. 13/13 patients (100%) of the 29 mCi group developed hypothyroidism in 2-4 months. Conclusion: Hypothyroidism develops at a similar rate after 20 and 29 mCi of 131I.


REFERENCES

  1. Vanderpump MPJ, Tunbridge WMG. The epidemiology of autoimmune thyroid disease. In: Volpe R, ed. Autoimmune endocrionopathies Vol. 15 of contemporary endocrinology. Totowa, N.J. Humana Press 1999: 141-162.

  2. Vanderpump MP, Tunbridge WM, French JM et al. The incidence of thyroid disorders in the community: a twenty year follow up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43:55-68.

  3. Geffner DL, Hershman JM. B adrenergic blockade for the treatment of hyperthyroidism. Am J Med 1992; 93:61-68.

  4. Wall JR. Graves’ disease is a multi-system autoimmune disorders in which extraocular muscle damage and connective tissue inflammation are variable features. Thyroid 2002; 12: 35-36.

  5. Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS. Graves’ disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med 1989; 87: 558-561.

  6. Ginsberg J. Diagnosis and management of Graves’ disease. CMAJ 2003; 168: 575-585.

  7. Toft AD. Clinical Practice. Subclinical hyperthyroidism. N Engl J Med 2001; 345: 512-516.

  8. Cooper DS. Antithyroid drugs for the treatment of hyperthyroidism caused by Graves’ disease. Endocrinol Metab Clin North Am 1998, 27: 225-247.

  9. Cooper DS. Which antithyroid drug? Am J Med 1986; 80: 1165-1168.

  10. Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence–based approach to therapeutic controversies. J Clin Endocrinol Metab 2003; 88: 3474-3481.

  11. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T et al. Administration of thyroxine in treated Graves’ disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991; 324: 947-953.

  12. Raber W, Kmen E, Waldhausl W, Vierhapper H. Medical therapy of Graves’ disease: effect on remission rates of methimazole alone and in combination with triiodothyronine. Eur J Endocrinol 2000; 142: 117-124.

  14. Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K et al. Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a randomized study on the use of thyroxine. Thyroid 2000; 12: 1119-1128.

  15. Glinoer D, Hesh D, LaGasse R. The management of hyperthyroidism due Graves´ disease in Europe 1986: results of a international survey. Acta Endocrinol 1987; 185 (suppl): 9-37.

  16. Kaplan M, Meier D, Dworkin H. Treatment of hyperthyroidism with radioactive iodine. Endocrinol Metab Clin North Am 1998; 27: 205-223.

  17. Sakar S, Beierwaltes W, Gills et al. Subsequent fertility and birth histories of children and adolescents treated with 131 I for thyroid cancer. J Nucl Med 1976; 17: 460-466.

  18. Hernández-Jiménez S, Pachón-Burgos A, Aguilar-Salinas CA, Andrade V, Reynoso R, Ríos A, Reza-Albarrán A et al. Radioiodine treatment in autoimmune hyperthyroidism: analysis of outcomes in relation to dosage. Arch Med Res 2007; 38: 185-189.

  19. Torres P, Normandia A, Ayala M, Gómez G, Serrano I, González D. Tratamiento del hipertiroidismo con una dosis de 10 milicuries de I131 en la enfermedad de Graves Basedow. Rev Endocrinol Nutr 1997; 5: 63-66.

  20. Hernández E, Torres P, Normandia M, Galindo M, Amador N, González D. Tratamiento del bocio tóxico difuso con dosis única de yodo radiactivo 131 calculada por el tamaño del bocio y las concentraciones séricas de triiodotironina (T3). Rev Endocrinol Nutr 2003; 11: 157-161.

  21. Cadavid L, Jario J, Medina R. Conversión a hipotiroidismo en tratamiento con I131 por hipertiroidismo secundario a enfermedad de Graves. Hospital San José, enero 2005- diciembre 2008. Repert Med Cir 2009; 18: 231-236.




2020     |     www.medigraphic.com